Ashland(ASH) - 2026 Q1 - Earnings Call Transcript

Financial Performance and Key Metrics - Sales for the quarter were $386 million, down 5% year-over-year, with the Avoca divestiture accounting for approximately $10 million of the decline [18] - Adjusted EBITDA was $58 million, down 5% year-over-year, reflecting lower volumes and modest pricing pressure, with adjusted EBITDA margins holding steady at 15% [19][21] - Adjusted EPS, excluding intangible amortization, was $0.26, down 7% from the prior year [22] - The company ended the quarter with total liquidity of approximately $900 million and net debt of $1.1 billion, maintaining a net leverage of 2.7x [23] Business Segment Performance - Life Sciences sales were $139 million, up 4% year-over-year, driven by resilient pharma demand and strong performance in injectables and tablet coatings [24][25] - Personal Care sales were $123 million, down 8% year-over-year, primarily due to the Avoca divestiture, with organic sales declining 1% [32] - Specialty Additives sales were $102 million, down 11% year-over-year, with coatings and construction driving the decline, particularly in China [38] - Intermediates sales were $31 million, down 6% year-over-year, with captive BDO sales declining due to lower volumes and pricing [30] Market Conditions - Demand in coatings and construction remained soft, particularly in China and select export markets, while personal care showed stable demand overall [8][10] - The company noted that the coatings market is expected to recover gradually, with mixed demand conditions anticipated [49][90] Company Strategy and Industry Competition - The company is focused on executing its strategic priorities, including innovation and global expansion, to drive growth and improve margins [15][46] - Cost actions and operational efficiencies are expected to support margin durability and position the company for stronger leverage as demand recovers [15][44] Management Commentary on Operating Environment and Future Outlook - Management expressed cautious optimism regarding demand recovery in the second quarter, with expectations for improved order volumes [68][70] - The company anticipates that operational challenges, including delays in the Calvert City unit startup, will impact performance but remain manageable [51][52] Other Important Information - The company is on track to achieve total cost savings of approximately $30 million for fiscal 2026, with ongoing productivity improvements expected [42][44] - Innovation remains a key driver of long-term growth, with several new product launches and advancements in technology platforms [54][61] Q&A Session Summary Question: Impact of customer outages on personal care demand - Management confirmed that customer outages were temporary and recoverable, with expectations to regain lost volumes in the second quarter [72][73] Question: Outlook for personal care volumes - Management indicated that with the Avoca divestiture now lapped, positive volume growth is expected as the year progresses [77] Question: China coatings demand outlook - Management noted that while the coatings market in China has faced challenges, there are signs of stabilization, and the company is well-positioned to capitalize on future opportunities [90][92] Question: Risks around global trade issues - Management highlighted Europe as a key area of focus regarding potential trade pressures, with ongoing discussions but no clear decisions yet [97]